Novel agents for advanced pancreatic cancer

Pancreatic cancer is relatively insensitive to conventional chemotherapy. Therefore, novel agents targeting dysregulated pathways (MAPK/ERK, EGFR, TGF-β, HEDGEHOG, NOTCH, IGF, PARP, PI3K/AKT, RAS, and Src) are being explored in clinical trials as monotherapy or in combination with cytotoxic chemotherapy. This review summarizes the most recent advances with the targeted therapies in the treatment of patients with advanced pancreatic cancer.

• Publication year

  2015

• Venue

  OncoTarget

• Publication date

  2015-06-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.18632/oncotarget.3999PMID 26369833PMCID 4741843
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma

  2019cited by this paper
• Oral tyrosine kinase inhibitor masitinib in combination with gemcitabine in patients with advanced pancreatic cancer: A multicenter phase II study.

  2016cited by this paper
• Novel ALK inhibitors in clinical use and development

  2015cited by this paper
• Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

  2015cited by this paper
• Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future

  2015cited by this paper
• A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.

  2015cited by this paper
• A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.

  2015cited by this paper
• A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma

  2014cited by this paper
• Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies

  2014cited by this paper
• CHIP is a novel tumor suppressor in pancreatic cancer and inhibits tumor growth through targeting EGFR

  2014cited by this paper
• Kras as a key oncogene and therapeutic target in pancreatic cancer

  2014cited by this paper
• Crizotinib Exhibits Antitumor Activity by Targeting ALK Signaling not c-MET in Pancreatic Cancer

  2014cited by this paper
• Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC).

  2014cited by this paper
• Phase II study of refametinib (BAY 86-9766), an allosteric dual MEK 1/2 inhibitor, and gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer.

  2014cited by this paper
• Feasibility and results of a randomized phase Ιb study of fractionated 90Υ-clivatuzumab tetraxetan in patients with metastatic pancreatic cancer having two or more prior therapies.

  2014cited by this paper
• Phase Ib of anticancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).

  2014cited by this paper
• Sirtainties in pancreatic cancer?

  2014cited by this paper
• Cancer statistics, 2014

  2014cited by this paper
• A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA).

  2014cited by this paper
• Dual blockade of epidermal growth factor receptor and insulin‐like growth factor receptor–1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)

  2014cited by this paper
• A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.

  2014cited by this paper
• Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

  2013cited by this paper
• Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer.

  2013cited by this paper
• Progress from clinical trials and emerging non-conventional therapies for the treatment of Medulloblastomas.

  2013cited by this paper
• Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with gemcitabine in patients with advanced cancer.

  2013cited by this paper
• Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer.

  2013cited by this paper
• Masitinib in nonresectable pancreatic cancer: Results of a phase III randomized placebo-controlled trial.

  2013influential reference
• Pancreatic cancer.

  2013cited by this paper
• Pimasertib plus gemcitabine in metastatic pancreatic adenocarcinoma: Results of a safety run-in part of a phase II trial.

  2013cited by this paper
• MEK and the inhibitors: from bench to bedside

  2013cited by this paper
• Dual MEK/EGFR inhibition for advanced, chemotherapy-refractory pancreatic cancer: A multicenter phase II trial of selumetinib (AZD6244; ARRY-142886) plus erlotinib.

  2013cited by this paper
• Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer

  2013cited by this paper
• Modest Improvement in Overall Survival for Patients With Metastatic Pancreatic Cancer: A Trend Analysis Using the Surveillance, Epidemiology, and End Results Registry From 1988 to 2008

  2013cited by this paper
• Prospective randomized phase II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: A study of the CESAR Central European Society for Anticancer Drug Research-EWIV.

  2013cited by this paper
• Final analysis of a phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): A University of Chicago phase II consortium study.

  2013influential reference
• First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors

  2013cited by this paper
• Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial

  2012cited by this paper
• Fractionated radioimmunotherapy with 90Y‐clivatuzumab tetraxetan and low‐dose gemcitabine is active in advanced pancreatic cancer

  2012cited by this paper
• BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer.

  2012cited by this paper
• A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.

  2012cited by this paper
• A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

  2012cited by this paper
• A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer.

  2012cited by this paper
• Global burden of cancer: opportunities for prevention.

  2012cited by this paper
• A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer

  2012cited by this paper
• Hedgehog signaling pathway mediates invasion and metastasis of hepatocellular carcinoma via ERK pathway

  2012cited by this paper
• Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

  2012cited by this paper
• Activation of Hedgehog pathway in gastrointestinal cancers.

  2012cited by this paper
• Developmental pathways in colon cancer

  2012cited by this paper
• Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.

  2012cited by this paper
• Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer

  2012influential reference
• Regulation of DNA Damage Following Termination of Hedgehog (HH) Survival Signaling at the level of the GLI Genes in Human Colon Cancer

  2012cited by this paper
• Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy

  2012cited by this paper
• Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer

  2012cited by this paper
• A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin enhance gemcitabine-induced apoptosis in pancreatic cancer cells.

  2011cited by this paper
• MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy.

  2011cited by this paper
• Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.

  2011cited by this paper
• A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors

  2011cited by this paper
• Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial

  2011cited by this paper
• Pancreatic Cancer Surgery in the New Millennium: Better Prediction of Outcome

  2011cited by this paper
• The use of PARP inhibitors as single agents and as chemosensitizers in sporadic pancreatic cancer.

  2011cited by this paper
• Hedgehog Signaling Antagonist GDC-0449 (Vismodegib) Inhibits Pancreatic Cancer Stem Cell Characteristics: Molecular Mechanisms

  2011cited by this paper
• FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

  2011cited by this paper
• Randomized phase II study of gemcitabine (G) plus anti-IGF-1R antibody MK-0646, G plus erlotinib (E) plus MK-0646 and G plus E for advanced pancreatic cancer.

  2011cited by this paper
• Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.

  2011cited by this paper
• Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts

  2010cited by this paper
• Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5)

  2010influential reference
• A Phase I Study of Weekly R1507, A Human Monoclonal Antibody Insulin-like Growth Factor-I Receptor Antagonist, in Patients with Advanced Solid Tumors

  2010cited by this paper
• Detection of Early-Stage Pancreatic Adenocarcinoma

  2010cited by this paper
• Masitinib Combined with Standard Gemcitabine Chemotherapy: In Vitro and In Vivo Studies in Human Pancreatic Tumour Cell Lines and Ectopic Mouse Model

  2010cited by this paper
• Salirasib in the treatment of pancreatic cancer.

  2010cited by this paper
• Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

  2010cited by this paper
• Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.

  2010cited by this paper
• Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti‐myeloma activity in vitro and in vivo

  2010cited by this paper
• Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types

  2010cited by this paper
• Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer.

  2010cited by this paper
• Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.

  2010cited by this paper
• Pancreatic cancer.

  2010cited by this paper
• Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.

  2010cited by this paper
• A phase Ib study to evaluate the safety and efficacy of AMG 655 in combination with gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (PC).

  2009cited by this paper
• A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer

  2009cited by this paper
• Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.

  2009cited by this paper
• Desmoplasia of pancreatic ductal adenocarcinoma.

  2009cited by this paper
• The hedgehog pathway and pancreatic cancer.

  2009cited by this paper
• Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.

  2009cited by this paper
• In vitro and In vivo Radiosensitization with AZD6244 (ARRY-142886), an Inhibitor of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase 1/2 Kinase

  2009cited by this paper
• Abstract A121: Novel PARP inhibitors with potent antitumor activity as single‐agent and combination therapies

  2009cited by this paper
• RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.

  2009cited by this paper
• GDC-0449-a potent inhibitor of the hedgehog pathway.

  2009cited by this paper
• Antitumor Effects and Biomarkers of Activity of AZD0530, a Src Inhibitor, in Pancreatic Cancer

  2009cited by this paper
• Prostate stem cell antigen: a prospective therapeutic and diagnostic target.

  2009cited by this paper
• Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT

  2009cited by this paper
• Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.

  2009cited by this paper
• Molecular mechanisms involved in activity of h7C10, a humanized monoclonal antibody, to IGF‐1 receptor

  2009cited by this paper
• Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers.

  2009cited by this paper
• Mechanisms of Hedgehog pathway activation in cancer and implications for therapy.

  2009cited by this paper
• Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

  2008cited by this paper
• Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial

  2008cited by this paper
• FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells.

  2008cited by this paper
• Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530

  2008cited by this paper
• A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes.

  2008influential reference

• Network pharmacology analysis and experimental verification of the antitumor effect and molecular mechanism of isocryptomerin on HepG2 cells

  2024influential citation
• Network pharmacology-based anti-pancreatic cancer potential of kaempferol and catechin of Trema orientalis L. through computational approach

  2023cites this paper
• Identification of matrix-remodeling associated 5 as a possible molecular oncotarget of pancreatic cancer

  2023cites this paper
• Mechanism investigation of fermented egg-milk peptides on colonic inflammatory diseases: based on in vivo and in silico research.

  2022cites this paper
• Translating Complexity and Heterogeneity of Pancreatic tumor: 3D In Vitro to In Vivo Models.

  2021cites this paper
• Elevated expression of nuclear receptor-binding SET domain 3 promotes pancreatic cancer cell growth

  2021cites this paper
• PMEPA1 stimulates the proliferation, colony formation of pancreatic cancer cells via the MAPK signaling pathway.

  2021cites this paper
• The natural product trienomycin A is a STAT3 pathway inhibitor that exhibits potent in vitro and in vivo efficacy against pancreatic cancer

  2021cites this paper
• Efficacy of Chemotherapy Integrated With Traditional Korean Medicine in Patients With Metastatic Pancreatic Cancer: A Single-Center Retrospective Study

  2020cites this paper
• Natural Product Trienomycin A is a STAT3 pathway inhibitor that exhibits potent in vitro and in vivo efficacy against pancreatic cancer

  2020cites this paper
• Prometastatic Secretome Trafficking via Exosomes Initiates Pancreatic Cancer Pulmonary Metastasis.

  2020cites this paper
• OTT_A_223221 8287..8299

  2019cites this paper
• Animal models for modeling pancreatic cancer and novel drug discovery

  2019cites this paper
• INPP4B As A Prognostic And Diagnostic Marker Regulates Cell Growth Of Pancreatic Cancer Via Activating AKT

  2019cites this paper
• Przeciwciała monoklonalne w regulacji transdukcji sygnału receptora naskórkowego czynnika wzrostu (EGFR) w komórkach nowotworowych

  2018influential citation
• Clinical update on K-Ras targeted therapy in gastrointestinal cancers.

  2018cites this paper
• Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer

  2017cites this paper
• Natural Products as Adjunctive Treatment for Pancreatic Cancer: Recent Trends and Advancements

  2017influential citation
• EGFR-induced phosphorylation of type Iγ phosphatidylinositol phosphate kinase promotes pancreatic cancer progression

  2017cites this paper
• MicroRNA-216b-5p Functions as a Tumor-suppressive RNA by Targeting TPT1 in Pancreatic Cancer Cells

  2017cites this paper
• TGF-β Signal Transduction in Pancreatic Carcinoma Cells is Sensitive to Inhibition by the Src Tyrosine Kinase Inhibitor AZM475271.

  2017cites this paper
• Ku70 inhibits gemcitabine-induced DNA damage and pancreatic cancer cell apoptosis.

  2017cites this paper
• A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer

  2017cites this paper
• The Molecular Connections between Lung and Pancreatic Cancer Metastases: are we not seeing the Forest for the Trees?

  2017influential citation
• Natural Products as Adjunctive Treatment for Pancreatic Cancer: Recent Trends and Advancements

  2017influential citation
• A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancer

  2017cites this paper
• TGFβ1 overexpression is associated with improved survival and low tumor cell proliferation in patients with early-stage pancreatic ductal adenocarcinoma

  2016cites this paper
• Novel regulatory role of neuropilin-1 in endothelial-to-mesenchymal transition and fibrosis in pancreatic ductal adenocarcinoma

  2016cites this paper
• Autologous cytokine-induced killer cell transfusion increases overall survival in advanced pancreatic cancer

  2016cites this paper
• The preclinical evaluation of TIC10/ONC201 as an anti-pancreatic cancer agent.

  2016cites this paper
• Challenges and Opportunities in Modeling Pancreatic Cancer.

  2016cites this paper
• Establishment of prostate cancer spheres from a prostate cancer cell line after phenethyl isothiocyanate treatment and discovery of androgen-dependent reversible differentiation between sphere and neuroendocrine cells

  2016cites this paper
• Pancreatic cancer : a therapeutic challenge

  year unknowncites this paper